[{"id":"3ba5c955-8ec9-4668-a6f6-e10f2a3b745e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07004075","created_at":"2025-06-07T14:43:33.080Z","updated_at":"2025-06-07T14:43:33.080Z","phase":"Phase 3","brief_title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","source_id_and_acronym":"NCT07004075","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • Ivesa (firmonertinib) • Fu Mai Ning (luvometinib) • vindesine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-06-04"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"858789a0-ffc7-4b5d-93c6-6eb6690616c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06553365","created_at":"2025-02-27T08:06:57.659Z","updated_at":"2025-02-27T08:06:57.659Z","phase":"Phase 2","brief_title":"Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors","source_id_and_acronym":"NCT06553365","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/15/2024","start_date":" 08/15/2024","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-08-14"},{"id":"567a8aef-1c29-45f6-aa4c-73624212b548","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932253","created_at":"2021-01-18T19:22:09.234Z","updated_at":"2024-07-02T16:35:12.608Z","phase":"Phase 1","brief_title":"MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)","source_id_and_acronym":"NCT03932253","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" NRAS • NF1","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Suspended","enrollment":" Enrollment 79","initiation":"Initiation: 03/21/2019","start_date":" 03/21/2019","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-03-27"},{"id":"5464bbe9-0507-491a-a174-c662a80c8226","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913037","created_at":"2023-06-22T19:11:30.805Z","updated_at":"2024-07-02T16:35:14.460Z","phase":"Phase 3","brief_title":"FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas","source_id_and_acronym":"NCT05913037","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 06/20/2023","start_date":" 06/20/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-03-15"},{"id":"2d1e326b-a843-4882-b48e-31d0ec882489","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005974","created_at":"2023-08-23T16:10:48.874Z","updated_at":"2024-07-02T16:35:20.791Z","phase":"Phase 2","brief_title":"A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation","source_id_and_acronym":"NCT06005974","lead_sponsor":"Recursion Pharmaceuticals Inc.","biomarkers":" APC • RAS • AXIN1","pipe":" | ","alterations":" APC mutation","tags":["APC • RAS • AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-4881"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-06"},{"id":"58b26f64-7b26-4c99-ba89-84483413fd67","acronym":"","url":"https://clinicaltrials.gov/study/NCT02367859","created_at":"2021-01-18T11:16:38.843Z","updated_at":"2025-02-25T15:42:16.020Z","phase":"Phase 2","brief_title":"Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma","source_id_and_acronym":"NCT02367859","lead_sponsor":"Stanford University","biomarkers":" ALK • RAF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["ALK • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 11/05/2018","primary_completion_date":" 11/05/2018","study_txt":" Completion: 06/26/2019","study_completion_date":" 06/26/2019","last_update_posted":"2024-01-30"},{"id":"fa6223ae-78f2-443c-a255-1f06c8ef7cf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05831995","created_at":"2023-04-27T14:04:51.130Z","updated_at":"2024-07-02T16:35:23.994Z","phase":"Phase 1","brief_title":"Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.","source_id_and_acronym":"NCT05831995","lead_sponsor":"ABM Therapeutics Corporation","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABM-168"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 10/16/2025","primary_completion_date":" 10/16/2025","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2024-01-10"},{"id":"71baff50-e314-4a96-b786-467f5f3dd5d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04954001","created_at":"2021-07-08T14:52:37.523Z","updated_at":"2024-07-02T16:35:33.023Z","phase":"Phase 2","brief_title":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","source_id_and_acronym":"NCT04954001","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 03/26/2021","start_date":" 03/26/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2023-10-17"},{"id":"87c14e4e-dad4-4085-ba55-6c5babc89000","acronym":"","url":"https://clinicaltrials.gov/study/NCT03843775","created_at":"2021-01-18T18:58:38.993Z","updated_at":"2024-07-02T16:35:38.031Z","phase":"Phase 1/2","brief_title":"A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers","source_id_and_acronym":"NCT03843775","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 09/02/2023","primary_completion_date":" 09/02/2023","study_txt":" Completion: 09/02/2023","study_completion_date":" 09/02/2023","last_update_posted":"2023-09-06"},{"id":"a2c8942c-0a0f-498b-8a5e-e033d78eebcf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008119","created_at":"2023-08-23T15:11:11.548Z","updated_at":"2024-07-02T16:35:39.252Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06008119","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 11/24/2023","start_date":" 11/24/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2023-08-23"},{"id":"df1aef8d-1125-430b-acad-455dcf473546","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008106","created_at":"2023-08-23T15:11:11.269Z","updated_at":"2024-07-02T16:35:39.195Z","phase":"Phase 3","brief_title":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","source_id_and_acronym":"NCT06008106","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • Kolupin (tunlametinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 09/22/2027","primary_completion_date":" 09/22/2027","study_txt":" Completion: 09/22/2027","study_completion_date":" 09/22/2027","last_update_posted":"2023-08-23"},{"id":"b5f5b451-b510-426e-bac7-2d14c444f59b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05900219","created_at":"2023-06-12T15:09:02.818Z","updated_at":"2024-07-02T16:35:45.895Z","phase":"Phase 2","brief_title":"Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study","source_id_and_acronym":"NCT05900219","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/24/2023","start_date":" 09/24/2023","primary_txt":" Primary completion: 09/24/2025","primary_completion_date":" 09/24/2025","study_txt":" Completion: 09/24/2025","study_completion_date":" 09/24/2025","last_update_posted":"2023-06-12"},{"id":"1f4a51be-fa8d-4049-af4e-50e1fb9f34d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05233332","created_at":"2022-02-10T14:52:59.343Z","updated_at":"2024-07-02T16:35:46.766Z","phase":"Phase 2","brief_title":"Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT05233332","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 01/20/2024","primary_completion_date":" 01/20/2024","study_txt":" Completion: 07/20/2024","study_completion_date":" 07/20/2024","last_update_posted":"2023-05-31"},{"id":"2e9c47f2-4cd8-4fc4-bb34-ab7a99f8abdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263453","created_at":"2022-03-02T16:52:42.865Z","updated_at":"2024-07-02T16:35:46.842Z","phase":"Phase 2","brief_title":"HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation","source_id_and_acronym":"NCT05263453","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 09/06/2021","start_date":" 09/06/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-05-31"},{"id":"395f67cd-671d-4041-abf3-eb347b1ee42b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05217303","created_at":"2022-02-05T18:28:11.143Z","updated_at":"2024-07-02T16:35:46.778Z","phase":"Phase 2","brief_title":"HL-085 in NRAS-mutated Advanced Melanoma","source_id_and_acronym":"NCT05217303","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kolupin (tunlametinib)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 11/02/2020","start_date":" 11/02/2020","primary_txt":" Primary completion: 02/19/2023","primary_completion_date":" 02/19/2023","study_txt":" Completion: 02/20/2023","study_completion_date":" 02/20/2023","last_update_posted":"2023-05-31"},{"id":"79812039-10e9-461b-948a-802649275a7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05331105","created_at":"2022-04-15T11:53:16.673Z","updated_at":"2024-07-02T16:35:46.830Z","phase":"Phase 2","brief_title":"HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","source_id_and_acronym":"NCT05331105","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2023-05-31"},{"id":"95b8e7e2-e4e3-46d3-bc40-10cb1c4e56cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03973151","created_at":"2021-01-17T17:54:22.805Z","updated_at":"2024-07-02T16:35:46.786Z","phase":"Phase 1/2","brief_title":"Study of HL-085 in NRAS Mutant Advanced Melanoma","source_id_and_acronym":"NCT03973151","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kolupin (tunlametinib)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 01/18/2021","primary_completion_date":" 01/18/2021","study_txt":" Completion: 01/18/2021","study_completion_date":" 01/18/2021","last_update_posted":"2023-05-31"},{"id":"d7c92316-5deb-4e26-acda-421b37ed17fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03781219","created_at":"2021-01-18T18:42:05.306Z","updated_at":"2024-07-02T16:35:46.774Z","phase":"Phase 1","brief_title":"A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation","source_id_and_acronym":"NCT03781219","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-05-31"},{"id":"22923149-06d3-45f2-a2f9-f7f680b159a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00794781","created_at":"2021-01-18T03:00:59.393Z","updated_at":"2024-07-02T16:36:02.453Z","phase":"Phase 1","brief_title":"A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT00794781","lead_sponsor":"Eisai Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E6201"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 06/22/2008","start_date":" 06/22/2008","primary_txt":" Primary completion: 08/01/2011","primary_completion_date":" 08/01/2011","study_txt":" Completion: 10/15/2015","study_completion_date":" 10/15/2015","last_update_posted":"2022-10-14"},{"id":"ce51dd71-f581-4b05-8883-08013dc38521","acronym":"","url":"https://clinicaltrials.gov/study/NCT05107037","created_at":"2021-11-04T16:57:13.962Z","updated_at":"2024-07-02T16:36:21.312Z","phase":"Phase 1","brief_title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis","source_id_and_acronym":"NCT05107037","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQ-B3234"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-11-04"},{"id":"83385b77-9ea5-4d67-9e51-7f9e43d6472e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03794297","created_at":"2021-01-18T18:45:38.324Z","updated_at":"2024-07-02T16:36:33.171Z","phase":"Phase 2","brief_title":"Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations","source_id_and_acronym":"NCT03794297","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • CRP","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["ER • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 02/18/2021","primary_completion_date":" 02/18/2021","study_txt":" Completion: 02/18/2021","study_completion_date":" 02/18/2021","last_update_posted":"2021-03-17"},{"id":"293aa130-f843-4e6e-b244-1c52e1d1dad3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324830","created_at":"2021-01-18T05:23:43.525Z","updated_at":"2024-07-02T16:37:04.485Z","phase":"Phase 1a/1b","brief_title":"Monotherapy Dose Finding With BI 847325 in Solid Tumours","source_id_and_acronym":"NCT01324830","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • RAS mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 847325"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 04/15/2011","start_date":" 04/15/2011","primary_txt":" Primary completion: 06/06/2013","primary_completion_date":" 06/06/2013","study_txt":" Completion: 10/10/2013","study_completion_date":" 10/10/2013","last_update_posted":"2018-12-21"},{"id":"56bf1530-3867-4ac6-bd63-b4d18ea65359","acronym":"","url":"https://clinicaltrials.gov/study/NCT02281734","created_at":"2021-10-27T09:53:25.922Z","updated_at":"2024-07-02T16:37:16.996Z","phase":"Phase 2","brief_title":"Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease and BRAF Mutation","source_id_and_acronym":"NCT02281734","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-19"}]